专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

151. 发明申请

US20100286160A1 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS 审中-公开
标题翻译：取代的PIPERAZINES作为CB1拮抗剂
公开(公告)号：US20100286160A1
公开(公告)日：2010-11-11
申请号：US12665253
申请日：2008-06-25
申请人： Eric J. Gilbert , William J. Greenlee , Sarah Wei Li , Michael W. Miller , Jack D. Scott , Adrew Stamford , Chander Shekher Celly
发明人： Eric J. Gilbert , William J. Greenlee , Sarah Wei Li , Michael W. Miller , Jack D. Scott , Adrew Stamford , Chander Shekher Celly
IPC分类号： A61K31/497 , C07D241/04 , C07D403/12 , C07D241/02 , C07D401/12 , C07D401/14 , A61P9/00
CPC分类号： C07D401/06 , C07D241/04
摘要： Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍和精神病，成瘾（例如吸烟停止），胃肠道疾病和心血管疾病。

152. 发明申请

US20100256128A1 GAMMA SECRETASE MODULATORS 有权
标题翻译： GAMMA秘密调节器
公开(公告)号：US20100256128A1
公开(公告)日：2010-10-07
申请号：US12601322
申请日：2008-05-28
申请人： Zhaoning Zhu , William J. Greenlee , Xianhai Huang , Brian A. McKittrick , John W. Clader , Mark D. McBriar , Anandan Palani
发明人： Zhaoning Zhu , William J. Greenlee , Xianhai Huang , Brian A. McKittrick , John W. Clader , Mark D. McBriar , Anandan Palani
IPC分类号： A61K31/5365 , C07D498/04 , A61K31/5395 , A61P25/28
CPC分类号： C07D498/04 , C07D403/10 , C07D471/04 , C07D487/04
摘要： In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.
摘要翻译：在其许多实施方案中，本发明提供了一类新颖的下式杂环化合物：作为γ-分泌酶的调节剂，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种这样的化合物的药物制剂的方法化合物，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与中枢神经系统相关的一种或多种疾病的方法。

153. 发明申请

US20100249144A1 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS 审中-公开
标题翻译：取代的PIPERAZINES作为CB1拮抗剂
公开(公告)号：US20100249144A1
公开(公告)日：2010-09-30
申请号：US12665250
申请日：2008-06-25
申请人： Duane Eugene Demong , Michael W. Miller , Eric J. Gilbert , Jack D. Scott , Andrew Stamford , William J. Greenlee , Chander Shekher Celly
发明人： Duane Eugene Demong , Michael W. Miller , Eric J. Gilbert , Jack D. Scott , Andrew Stamford , William J. Greenlee , Chander Shekher Celly
IPC分类号： A61K31/496 , C07D241/04 , A61K31/495 , C07D401/06 , A61P25/28 , A61P25/16 , A61P25/06 , A61P25/08 , A61P25/02 , A61P25/18 , A61P25/22 , A61P25/32 , A61P25/34 , A61P35/00 , A61P1/00 , A61P1/08 , A61P1/12 , A61P3/10 , A61P3/04 , A61P29/00 , A61P15/10
CPC分类号： C07D241/04 , C07D213/30 , C07D401/06
摘要： Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍和精神病，成瘾（例如戒烟），胃肠道疾病和心血管疾病。

154. 发明授权

US07713999B2 Thrombin receptor antagonists 有权
标题翻译：凝血酶受体拮抗剂
公开(公告)号：US07713999B2
公开(公告)日：2010-05-11
申请号：US11733635
申请日：2007-04-10
申请人： Samuel Chackalamannil , Martin C. Clasby , William J. Greenlee , Yuguang Wang , Yan Xia , Enrico P. Veltri , Mariappan V. Chelliah
发明人： Samuel Chackalamannil , Martin C. Clasby , William J. Greenlee , Yuguang Wang , Yan Xia , Enrico P. Veltri , Mariappan V. Chelliah
IPC分类号： A61K31/443 , C07D307/78
CPC分类号： C07D405/06 , C07D405/14 , C07D417/14
摘要： Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R13 and R14; R13 and R14 are independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, —OH, (C1-C6)alkoxy, R27-aryl(C1-C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R13 and R14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
摘要翻译：具有下式的杂环取代的三环或其药学上可接受的盐，其中：虚线表示任选的单键; 表示可选的双键，n为0-2; Q是环烷基，任选被R 13和R 14取代; R 13和R 14独立地选自（C 1 -C 6）烷基，（C 3 -C 8）环烷基，-OH，（C 1 -C 6）烷氧基，R 27 - 芳基（C 1 -C 6）烷基，杂芳基，杂芳基烷基，杂环基，杂环基烷基，卤素和卤代烷基; 或R 13和R 14一起形成3-6个原子的螺环或异环环，Het是单或双环任选取代的杂芳基; 和B是键，亚烷基或任选取代的亚烯基或亚炔基，其中剩余的取代基如说明书中所定义，以及含有它们的药物组合物和治疗与血栓形成，动脉粥样硬化，再狭窄有关的疾病的方法，高血压，心绞痛，心律失常，心力衰竭和癌症。还要求与其它心血管药物联合治疗。

155. 发明授权

US07700603B2 Heterocyclic aspartyl protease inhibitors 有权
公开(公告)号：US07700603B2
公开(公告)日：2010-04-20
申请号：US11149027
申请日：2005-06-09
申请人： Zhaoning Zhu , Brian A McKittrick , Zhong-Yue Sun , Yuanzan C Ye , Johannes H Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter , Michelle L. Morris , Gang Qian , Dawit Tadesse
发明人： Zhaoning Zhu , Brian A McKittrick , Zhong-Yue Sun , Yuanzan C Ye , Johannes H Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X. H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter , Michelle L. Morris , Gang Qian , Dawit Tadesse
IPC分类号： A01N43/54 , C07D239/02 , C07D239/42 , C07D401/04
CPC分类号： C07D233/46 , C07D233/70 , C07D233/88 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D401/04 , C07D401/08 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/10 , C07D409/04 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

156. 发明申请

US20100029607A1 Substituted Piperazines as CB1 Antagonists 失效
标题翻译：取代的Piperazines作为CB1拮抗剂
公开(公告)号：US20100029607A1
公开(公告)日：2010-02-04
申请号：US12564678
申请日：2009-09-22
申请人： Eric J. Gilbert , Michael W. Miller , Jack D. Scott , Andrew W. Stamford , William J. Greenlee , Jay Weinstein
发明人： Eric J. Gilbert , Michael W. Miller , Jack D. Scott , Andrew W. Stamford , William J. Greenlee , Jay Weinstein
IPC分类号： A61K31/496 , C07D295/06 , C07D401/04 , C07D405/06 , C07D409/14 , A61K31/4965 , A61P3/00 , A61P25/00 , A61K31/397
CPC分类号： C07D241/04 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/08 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10
摘要： Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍和精神病，成瘾（例如吸烟停止），胃肠道疾病和心血管疾病。

157. 发明申请

US20090258868A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS 有权
标题翻译：异源ASPARTYL蛋白酶抑制剂
公开(公告)号：US20090258868A1
公开(公告)日：2009-10-15
申请号：US12331787
申请日：2008-12-10
申请人： Zhaoning Zhu , Brian A. McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X.H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter , Michelle L. Morris , Huizhong Gu , Gang Qian , Dawit Tadesse
发明人： Zhaoning Zhu , Brian A. McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew Stamford , William J. Greenlee , Robert Mazzola , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X.H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter , Michelle L. Morris , Huizhong Gu , Gang Qian , Dawit Tadesse
IPC分类号： A61K31/5355 , C07D401/02 , A61K31/4439 , C07D233/02 , A61K31/4166 , C07D239/24 , A61K31/505 , C07D241/10 , A61K31/497 , C07D261/02 , A61K31/42 , A61K31/454 , C07D277/20 , A61K31/426 , C07D235/04 , A61K31/4184 , C07D211/00 , A61K31/4545 , C07D471/02 , A61K31/4375 , C07D413/14 , A61K31/5377 , C07D487/02 , A61K31/519 , C07D271/06 , A61K31/4245 , C07D273/04 , A61P9/00 , A61P25/00
CPC分类号： C07D233/46 , C07D233/70 , C07D233/88 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D401/04 , C07D401/08 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/10 , C07D409/04 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
摘要翻译：公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中W是键，-C（-S） - ， - S（O） - ， - S（O） -C（ - ） - ， - O - ， - C（R6）（R7） - ， - N（R5） - 或-C（-N（R5） X是-O - ， - N（R 5） - 或-C（R 6）（R 7） - ; 条件是当X是-O-时，U不是-O-，-S（O） - ， - S（O）2 - ， - C（-O） - 或-C（-NR 5） - ; U是一个键，-S（O） - ， - S（O）2 - ， - C（O） - ， - O - ， - （O）（OR 15） - ， - （C（R6）（R7））b-或-N（R5） - ; 其中b为1或2; 条件是当W是-S（O） - ， - S（O）2 - ， - O-或-N（R 5） - 时，U不是-S（O） - ， - S（O） -O-或-N（R 5） - ; 条件是当X为-N（R5） - 且W为-S（O） - ， - S（O）2 - ， - O-或-N（R5） - 时，则U不为键; 并且R1，R2，R3，R4，R5，R6和R7如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D 和原生动物酶。还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

158. 发明授权

US07504391B2 Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders 失效
标题翻译：选择性D1 / D5受体拮抗剂用于治疗肥胖和CNS疾病
公开(公告)号：US07504391B2
公开(公告)日：2009-03-17
申请号：US10850530
申请日：2004-05-20
申请人： Duane A. Burnett , William J. Greenlee , Brian McKittrick , Jing Su , Zhaoning Zhu , Thavalakulamgara K. Sasikumar , Robert Mazzola , Li Qiang , Yuanzan Ye
发明人： Duane A. Burnett , William J. Greenlee , Brian McKittrick , Jing Su , Zhaoning Zhu , Thavalakulamgara K. Sasikumar , Robert Mazzola , Li Qiang , Yuanzan Ye
IPC分类号： A61P1/00 , A61K31/55 , C07D223/14 , C07D223/16
CPC分类号： C07D223/14
摘要： The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
摘要翻译：本发明提供了作为D1 / D5受体的新型拮抗剂的化合物以及制备这些化合物的方法。在另一个实施方案中，本发明提供包含这种D1 / D5受体拮抗剂的药物组合物以及使用它们治疗CNS障碍，肥胖，代谢紊乱，进食障碍如食欲过盛和糖尿病的方法。

159. 发明授权

US06630475B2 Adenosine A2a receptor antagonists 有权
标题翻译：腺苷A2a受体拮抗剂
公开(公告)号：US06630475B2
公开(公告)日：2003-10-07
申请号：US09865071
申请日：2001-05-24
申请人： Bernard R. Neustadt , Neil Lindo , William J. Greenlee , Deen Tulshian , Lisa S. Silverman , Yan Xia , Craig D. Boyle , Samuel Chackalamannil
发明人： Bernard R. Neustadt , Neil Lindo , William J. Greenlee , Deen Tulshian , Lisa S. Silverman , Yan Xia , Craig D. Boyle , Samuel Chackalamannil
IPC分类号： C07D40314
CPC分类号： C07D487/14
摘要： Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or —C(O)CH2—; Y is —N(R2)CH2CH2N(R)3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—NH—, or optionally substituted m and n are 2-3, and Q is nitrogen or optionally substituted carbon; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R6—C(O)—, R6—SO2—, R6—OC(O)—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)—, phenyl-CH(OH)—, or phenyl-C(═NOR2)—; or when Q is CH, phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl or substituted phenyl; and R2, R3, R6, R7, and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I.
摘要翻译：具有结构式I的化合物或其药学上可接受的盐，其中R是任选取代的苯基，环烯基或杂芳基; X是亚烷基或-C（O）CH 2 - ; Y是-N（R 2）CH 2 CH 2 N（R） 3） - ，-OCH 2 CH 2 N（R 2） - ， - O - ， - S - ， - CH 2 S - ， - （CH 2）2 -NH-或任选地被取代的n和n是2-3，并且Q是氮或任选取代的碳; 和Z是任选取代的苯基，苯基烷基或杂芳基，二苯基甲基，R 6 -C（O） - ，R 6 -SO 2 - ，R 6 -OC（O） - ，R 7 -N C（O） - ，R 7 -N（R 8）-C（S） - ，苯基-CH（OH） - 或苯基-C（= NOR 2） ; 或当Q为CH时，为苯基氨基或吡啶基氨基; 或Z和Y一起是取代的哌啶基或取代的苯基; 和R 2，R 3，R 6，R 7和R 8如说明书中所定义，其用于治疗帕金森病，单独使用或与其它药剂组合用于治疗帕金森病，以及包含它们的药物组合物; 还公开了制备可用于制备式I化合物的中间体的方法。

160. 发明授权

US6091168A Rotor for a dynamoelectric machine 有权
标题翻译：转子用于电动机
公开(公告)号：US6091168A
公开(公告)日：2000-07-18
申请号：US218653
申请日：1998-12-22
申请人： David G. Halsey , Hassan Mansir , Robert Grennan , William J. Greenlee , Dam Nguyen
发明人： David G. Halsey , Hassan Mansir , Robert Grennan , William J. Greenlee , Dam Nguyen
IPC分类号： H02K1/24 , H02K1/32 , H02K9/02 , H02K9/00
CPC分类号： H02K1/32 , H02K1/24 , H02K9/02
摘要： Losses in efficiency of operation of a dynamoelectric machine as a result of eddy current losses and poor coolant efficiency and/or disruption of the magnetic circuit in a rotor by coolant passages is avoided in a dynamoelectric machine including a stator (18) in which a rotor (16) is journaled. The rotor includes a stack (16) of thin laminations (17) made of a ferromagnetic material to define a rotor body. The rotor body includes a plurality of equally angularly spaced poles (58) separated by recesses (64). Coolant passages (76) located in the rotor at or just radially inward of the base (72) of each pole (58) and substantially radially outward of the rotational axis (56) of the rotor (14) to maximize cooling efficiency of the poles (58) without disrupting the magnetic circuit in the rotor. Slots (80) are placed in the tips (70) of the poles (58) of selected laminations (17) and extend generally radially inward to reduce eddy current losses.
摘要翻译：在包括定子（18）的电动机中避免了由于涡流损失和冷却剂效率差和/或由冷却剂通道引起的转子中的磁路的破坏导致的电动机的操作效率的损失，其中转子（16）记录。转子包括由铁磁材料制成的薄的叠片（17）的叠层（16），以形成转子体。转子主体包括由凹部（64）分开的多个等角度间隔的极（58）。冷却剂通道（76）位于转子的每一极（58）的基部（72）处或位于转子的径向内侧，并且基本上位于转子（14）的旋转轴线（56）的径向外侧，以使极点的冷却效率最大化（58），而不破坏转子中的磁路。狭槽（80）被放置在所选择的叠片（17）的极（58）的尖端（70）中，并且大致径向向内延伸以减少涡流损耗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式